This page is the primary source of information for your migration steps and resources. Always start with this page to contact us with questions, find dates and take action on confirming your status.

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced positive results from cohort 4 of the ...

Interim Pivotal Cohort 4 Results Initial results from the pivotal Cohort 4 in the C-144-01 clinical study is available for 68 patients with two radiological assessments, as determined by investigator.

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech (ONCY) ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today ...

(RTTNews) - Corvus Pharmaceuticals, Inc. (CRVS) is set to announce new data today from Cohort 4 of its ongoing placebo-controlled Phase 1 clinical trial evaluating Soquelitinib. Soquelitinib, the ...

UAB Medicine’s Leadership Development Office (LDO) honored 33 graduates of the Emerging Leaders Series (ELS) fall 2025 Cohort 4 during a ceremony held on Wednesday, Nov. 12. The cohort completed a ...

75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and 33% achieved IGA 0/1 Cohort 1-4 have demonstrated positive safety and efficacy results in patients who have received prior ...

Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up Cohort 2 Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up and ...